Caris Life Sciences (CAI) Operating Expenses (2024 - 2026)

Caris Life Sciences' Operating Expenses history runs 3 years deep, the most recent figure standing at $210.9 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 17.9% year-over-year to $210.9 million in Q1 2026; TTM through Mar 2026 was $798.9 million, a 18.3% increase from a year earlier, with the FY2025 full-year figure at $766.9 million, up 14.57% from the prior year.
• Operating Expenses rose to $210.9 million in Q1 2026 per CAI's latest filing, from $204.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $210.9 million in Q1 2026 and bottomed at $162.5 million in Q3 2024.
• The 3-year median for Operating Expenses is $181.5 million (2025), against an average of $184.3 million.
• Biggest YoY gain for Operating Expenses was 22.47% in 2025; the steepest drop was 13.37% in 2025.
• Year by year, Operating Expenses stood at $167.0 million in 2024, then grew by 22.47% to $204.5 million in 2025, then increased by 3.14% to $210.9 million in 2026.
• Per Business Quant, the three latest CAI Operating Expenses figures stand at $210.9 million (Q1 2026), $204.5 million (Q4 2025), and $184.2 million (Q3 2025).